Intelligent Bio Solutions Inc. achieved $4.2 million in Revenue for fiscal 2026, marking a 38% increase year-over-year. This growth underscores significant Demand for its testing solutions and sets the stage for anticipated FDA submissions for market expansion.
Key Highlights
- Intelligent Bio Solutions reported total revenue of $4,215,175, reflecting a 38% increase from the previous year.
- The company expanded its reader installed base by 22% to 1,886 units, driving a 35% increase in consumable cartridges to 106,500.
- Gross profit margin improved 778 basis points to 48.63%, supported by a strategic transition to a new Manufacturing partner.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) reported its financial results for the fiscal year ending June 30, 2026, achieving total revenue of $4.2 million. This figure represents a strong 38% increase compared to the previous year’s revenue of approximately $3.05 million. The surge in revenue was largely driven by a notable expansion in the company’s reader installed base, which grew by 22% to reach 1,886 units.
The strong demand indicates a growing market acceptance of its non-invasive testing solutions, significantly enhancing the company's revenue-generating capabilities.
Revenue Drivers
The revenue growth can be attributed to a 35% increase in total consumable cartridges, which rose to over 106,500 units. The company’s Business model, typically characterized by its razor-razorblade strategy, allows for hardware sales to generate a customer base while sustaining ongoing revenue through consumable sales. These increasing consumable cartridge volumes highlight a solid customer engagement and repeat purchasing habit, which are vital for establishing long-term financial sustainability.
This momentum suggests that Intelligent Bio Solutions is effectively leveraging its technologies in the healthcare testing environment, translating operational efficiencies into notable revenue growth.
Profitability Improvements
Intelligent Bio Solutions reported a gross profit of $2,049,994, representing a significant 64% increase from the previous year’s $1,246,859. The Gross Profit Margin enhanced to 48.63%, marking a steep rise of 778 basis points compared to 40.85% the year prior. This improvement is largely attributed to the transition to a lower-cost manufacturing partner, Syrma Johari, which has enabled the company to optimize its product mix toward higher-margin cartridge consumables.
Increased operational efficiencies from scaled production further bolster profitability, signifying a shift toward stronger unit Economics as production volumes continue to rise. The focus on reducing manufacturing costs while enhancing product margins supports a healthier financial outlook for the company.
Regulatory Progress
During fiscal 2026, Intelligent Bio Solutions made substantial advances toward obtaining FDA clearance for its products, which would facilitate entry into the significant U.S. drug screening market. The completion of several critical studies, including clinical studies and penetration testing, underscores the company’s commitment to regulatory compliance and technological reliability. The company is on track for a planned FDA submission during the second half of this calendar year.
Achieving this clearance is key not just for market entry but also for solidifying its competitive position in a lucrative sector poised for growth.
Future Prospects
Looking ahead, Intelligent Bio Solutions is focused on sustaining operational improvements, accelerating commercial growth, and advancing its regulatory affairs in preparation for market expansion. The company’s strategic priorities set the stage for further scalability and profitability as it prepares its FDA 510(k) submission. Continuous monitoring of customer engagement and inventory utilization will be important as the installed base grows, creating an environment ripe for sustained revenue generation.
Upcoming developments, particularly related to the FDA submission process, are expected to be closely watched by investors as they could significantly impact the company’s trajectory in the burgeoning healthcare environment.
Peers Moving on This News
- HeartSciences Inc. (NASDAQ: HSCS) up 17.4%
- Co-Diagnostics, Inc. (NASDAQ: CODX) up 2.4%






Please wait processing your request...